Kymera Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024, on February 27, 2025. The company provided a business update alongside its financial disclosures, focusing on the progress of its immunology pipeline.
Key pipeline updates included the ongoing KT-621 (STAT6) Phase 1 healthy volunteer trial, with complete SAD/MAD data expected in June 2025. The KT-621 Phase 1b trial in atopic dermatitis (AD) patients is expected to initiate in the second quarter of 2025, with data anticipated in the fourth quarter of 2025. This will be followed by two parallel Phase 2b trials in AD and asthma, starting in the fourth quarter of 2025 and the first quarter of 2026, respectively.
Additionally, the KT-295 (TYK2) Phase 1 trial is expected to start in the second quarter of 2025, with data anticipated in the fourth quarter of 2025. The partnered KT-474/SAR444656 (IRAK4) Phase 2b trials in hidradenitis suppurativa (HS) and AD are ongoing, led by Sanofi. The company's cash position and runway were also discussed, providing context for future development plans.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.